Hepatitis B is closely related to liver cancer, and our country is a major hepatitis B country. Therefore, for patients infected with hepatitis B virus, regular treatment of hepatitis B and regular checkups are especially important to prevent and treat liver cancer. When a healthy person is infected with hepatitis B virus, it does not necessarily lead to hepatitis, which is related to the viral load and the immunity of the body. Acute hepatitis occurs only when the viral load is too high and the body’s immunity is low, after which it turns into chronic hepatitis. Therefore, for those who do not have inflammation (i.e., significant destruction of liver cells) we call them hepatitis B carriers. For the former, we need antiviral treatment and hepatoprotective therapy, while for the latter, regular review and close follow-up is sufficient. Oral nucleic acid inhibitors (e.g., lamivudine, adefovir, entecavir, etc.) are preferred for treatment. This is because these drugs are easy to take (one tablet once a day), effective, have few side effects, and are relatively economical. However, these drugs need to be taken under the guidance of a professional doctor, and they need to be taken on a long-term basis and on time, and cannot be stopped at will to prevent the possibility of viral resistance or even outbreak of hepatitis. The results of foreign studies are that patients are recommended to take them for life. This is because it can not only effectively control the replication of the virus, but also slow down the process of liver fibrosis and cirrhosis, and even beneficially reduce the incidence of liver cancer, the recurrence rate after treatment, and prolong the survival time of liver cancer patients after treatment. An important drawback of these drugs is that resistance caused by viral mutation can occur after taking them for a period of time. Therefore, regular testing of hepatitis B two-to-one, liver function and HBV-DNA, and checking for viral mutation if necessary, are needed to determine whether mutation has occurred, and then timely change of medication according to doctors’ recommendations. With the development of drug research, new drugs are constantly being introduced and have the advantage of being increasingly efficient, safe and with low mutation rates. Interferons are also an important class of drugs for controlling the hepatitis B virus and have been shown to be useful in the treatment of liver cancer. They still need to be used under the supervision of a medical professional. For younger patients, these drugs can be preferred because there is no problem of drug resistance. However, they are relatively expensive and less convenient to use than oral drugs, and should not be used for patients with cirrhosis who have poor liver function. For patients with abnormal liver function, in addition to antiviral therapy, liver-protective support therapy is also important. We do not recommend multiple hepatoprotective drugs to be stacked on top of each other. We should select 1-2 appropriate hepatoprotective drugs for the treatment of abnormal liver function, and try to take oral treatment as much as possible, and infusion therapy only when necessary. At the same time, hepatitis B patients and virus carriers should avoid overworking, exercise properly, reduce the intake of fatty foods, and quit smoking and drinking, and develop good regular habits of work and rest. Let hepatitis be stable and let liver cancer stay away. Both hepatitis B patients and simple virus carriers have the chance to develop liver cancer, and even patients with only one positive hepatitis B virus serum half-indicator (except those who have been vaccinated with hepatitis B vaccine and have positive hepatitis B surface antibody) are still not completely immune. Therefore, in addition to regular antiviral treatment, regular review is needed to understand the situation of virus and hepatitis and to detect potential cancer at an early stage for the best treatment effect. According to the Ministry of Health’s “Standard for the Treatment of Primary Liver Cancer” (2011 version), it is recommended that for people infected with hepatitis B or C virus, especially for men >40 years old or women >50 years old, especially those with combined alcoholism, combined diabetes and family history of liver cancer, in addition to the examination of hepatitis indicators, routine monitoring and screening should be performed every 6 months: including serum fetoprotein ( alpha-fetoprotein (AFP) and liver ultrasonography (US). This is because the five-year survival rate after surgical resection for early-stage liver cancer can reach or even exceed 80 percent. In contrast, for mid- to late-stage liver cancer, this rate may be less than 30%, even if there is no chance of receiving radical treatment such as surgical resection. Therefore, we should pay attention to the protection and treatment of hepatitis virus infection, mainly hepatitis B virus, and pay more attention to regular and strict regular checkups, so that we can stay away from hepatitis and cancer, cherish our bodies and care for our lives.